Clinical Trials

A Phase 1, Multi-center, Open-label Study to Assess the Safety, Pharmacokinetics, and Preliminary Efficacy of an Orally Available Small Molecule, CC-99282, Alone and in Combination with Rituximab in Subjects with Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL)


Study ID
CC-99282-NHL-001

NCT Number
NCT03930953 (Click on the NCT number for more information about the trial)

Research Study Number
2019-0067

Principle Investigator
Dr. Tatyana Feldman

Phase
I

Sponsor
Celgene


Other protocol defined inclusion/exclusion criteria could apply If you are a physician and would like more details about this study, please contact us at JTCCResearch@HackensackMeridian.org

Apply Now